Lanvis (Tioguanine)

Tioguanine is a purine analog that is incorporated into DNA during the S‑phase of cell division. This incorporation disrupts normal base pairing, leading to faulty DNA synthesis and triggering apoptosis in rapidly dividing cells such as malignant lymphoblasts, myeloid cells, and immune cells involved in graft rejection.

The dosage of Lanvis is individualized by the treating physician based on the specific indication, patient weight, renal and hepatic function, and concurrent therapies. Prescribers calculate the appropriate amount and schedule, and the medication is supplied in tablet form for oral administration according to that professional guidance.

Safety data for tioguanine during pregnancy and lactation are limited. Because the drug can affect rapidly dividing fetal cells and may be excreted in breast milk, it is generally avoided unless the potential benefit outweighs the risk. Decisions should be made by the prescribing clinician in consultation with the patient.

To place an order, submit an enquiry on the Lanvis product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lanvis (tioguanine) belongs to the purine analog class, whereas alternatives such as azathioprine or mycophenolate mofetil are also antimetabolites but differ in metabolic activation and toxicity profiles. Tioguanine tends to have a higher risk of hepatic toxicity, while azathioprine may cause more pronounced bone‑marrow suppression. Choice depends on disease, tolerance and physician experience.

Lanvis tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discolored. No special refrigeration is required.

Lanvis is taken orally, usually with a glass of water. The tablets can be swallowed whole or, if necessary, divided according to the prescriber’s instructions. Administration should follow the dosing schedule set by the healthcare provider, and patients should adhere to any dietary or timing recommendations to optimize absorption and minimize gastrointestinal irritation.

The most serious adverse events linked to tioguanine include severe bone‑marrow suppression (neutropenia, thrombocytopenia, anemia), hepatotoxicity that can progress to liver failure, opportunistic infections due to immunosuppression, and, rarely, secondary malignancies. Patients should be monitored closely with regular blood counts and liver function tests to detect these complications early.

Lanvis is contraindicated in patients with known hypersensitivity to tioguanine or other purine analogs, those with active severe infections, and individuals with significant hepatic or renal impairment that cannot be corrected. It should also be avoided in pregnant women unless absolutely necessary, and in patients receiving other myelosuppressive agents without careful monitoring. Clinicians must evaluate each patient’s medical history before prescribing.